Mochi Health vs Trimi 2026: Which GLP-1 Provider Is Actually Cheaper?

Mochi Health vs Trimi: Side-by-Side Comparison

The table below covers every major decision factor — pricing, medications, formats, fees, support, and shipping. All prices reflect 2026 out-of-pocket costs without insurance.

The Membership Fee: Mochi's Hidden Cost

The single most important number to understand when comparing Mochi Health and Trimi is not the medication price — it is the membership fee. Mochi Health charges $79 per month for platform access, and this fee applies on top of whatever you pay for medication. When you see Mochi advertise compounded semaglutide at $99 per month, that is technically accurate — but your actual monthly bill is $178 once the membership is included.

For patients on tirzepatide, the math is even more striking. Mochi's tirzepatide is $199 per month plus the $79 membership, bringing the real monthly cost to $278. Trimi's compounded tirzepatide at $125 per month — with no membership fee, no hidden charges, and free shipping — represents a savings of $153 per month for the same class of medication. Over a 12-month treatment period, that adds up to $1,836 in annual savings.

This is not a criticism of the Mochi membership as a product. The membership funds a large clinical and community infrastructure, including their 140,000-member Facebook group and extensive platform features. But patients deserve to understand the true all-in cost before comparing providers. Trimi's pricing philosophy is the opposite: the price you see is the price you pay, period.

Annual Savings: What the Numbers Actually Mean

GLP-1 therapy is a long-term commitment. Most clinical evidence for meaningful, sustained weight loss comes from trials lasting 68 weeks or longer. When you calculate the cost difference between Mochi Health and Trimi over a realistic treatment timeline, the financial impact becomes very concrete.

These are not theoretical savings — they are the direct result of Trimi's no-membership-fee model applied to the same compounded GLP-1 medications. Whether a patient uses those savings to cover other health expenses, build an emergency fund, or reinvest in nutrition and fitness resources, the financial flexibility is real and meaningful. For a broader look at how GLP-1 costs compare to brand-name options like Wegovy, the difference is even more dramatic.

Medication Formats: Injectable vs Sublingual

One area where Mochi Health offers something Trimi does not is the sublingual format for compounded semaglutide. Sublingual medications are placed under the tongue and absorbed through the mucous membranes, eliminating the need for a weekly self-injection. For patients who are needle-averse or uncomfortable with subcutaneous injections, this is a meaningful option.

That said, it is important for patients to understand the clinical trade-offs. The subcutaneous injectable route — which Trimi uses — has the most robust clinical evidence base. Every major GLP-1 trial, including STEP 1 for semaglutide and SURMOUNT-1 for tirzepatide, used subcutaneous injection. The bioavailability, dosing precision, and weight loss outcomes associated with injectable GLP-1 are well-documented across tens of thousands of patients in controlled trials.

Sublingual GLP-1 is a newer compounded format with limited independent clinical trials specifically evaluating bioavailability and weight loss outcomes compared to the injectable route. Compounding pharmacies have developed proprietary formulations, but the peer-reviewed evidence base for sublingual semaglutide is not yet comparable to the injectable literature. This does not mean sublingual is ineffective — many patients report good results — but patients should weigh clinical evidence alongside format preference. For a complete breakdown of semaglutide side effects and what to expect, both injectable and sublingual routes carry similar risk profiles.

For patients who have no issue with self-injection, the injectable route provides the highest confidence in clinical outcomes at the lowest cost. Trimi's injectable compounded semaglutide at $99 per month total cost reflects this straightforward, evidence-aligned approach.

Mochi's Community and Review Volume: What They Signal

Mochi Health has built one of the most recognizable patient communities in the GLP-1 telehealth space. Their 140,000-plus member Facebook group is genuinely active, with patients sharing dosing experiences, side effect management tips, recipe ideas, and encouragement. For patients who find community support motivating, this is a real differentiator.

The 14,000-plus Trustpilot reviews represent a significant volume of patient feedback. Review volume correlates with platform age and scale more than with quality per se — a provider with more patients will accumulate more reviews — but the sheer number does signal that Mochi has helped a large population of patients navigate GLP-1 therapy. Reading through the reviews shows a mix of strong successes alongside the expected distribution of dissatisfied customers, particularly around customer service response times and administrative issues.

The important question is whether community scale and review volume are worth the premium price. For many patients, they are not — the community support they need comes from a provider who answers their clinical questions clearly and promptly, not from a large peer forum. Free GLP-1 communities on Reddit (r/WeightLossAdvice, r/Semaglutide) provide much of the peer support value at zero additional cost. Clinical questions are best answered by providers, not community members. Trimi's model directs that financial resource toward keeping medication costs low rather than building social infrastructure.

Winner by Category

Every patient's priorities differ. Here is an honest breakdown of where each platform wins:

Who Should Choose Mochi Health

Despite Trimi's clear pricing advantage, Mochi Health is a legitimate platform that will be the right fit for a subset of patients. Here is an honest look at who benefits most from Mochi's model.

Who Should Choose Trimi

Trimi's model is purpose-built for patients who want effective, clinically supervised GLP-1 therapy at the lowest defensible price point. The platform excels for a clear patient profile.

For patients in the middle — unsure whether community features or format flexibility matter to them — it is worth starting with the lower-cost option and seeing whether you miss the features you did not pay for. Switching from Trimi to Mochi is always possible later; switching from Mochi to Trimi while realizing you never used the community saves real money. Learn more about how Trimi compares across all major GLP-1 providers in our comprehensive 2026 ranking.

Are Compounded GLP-1 Medications Safe?

Both Mochi Health and Trimi use compounded GLP-1 medications — not FDA-approved brand-name products like Wegovy or Zepbound. Understanding what compounded means is important for any patient choosing between these platforms.

Compounded medications are prepared by licensed pharmacies using the same active pharmaceutical ingredients (semaglutide or tirzepatide) as the brand-name products. They are not FDA-approved as finished drug products, but they are dispensed by licensed 503B outsourcing facilities that operate under FDA oversight and conduct potency and sterility testing. The compounded versions are not identical to brand-name products — they do not use the same delivery system or undergo the same approval process — but for most patients, the active ingredient and dosing protocol are equivalent.

The cost difference between compounded and brand-name GLP-1 is enormous. While Wegovy can cost over $1,300 per month without insurance, compounded semaglutide at Trimi costs $99 total. For a detailed comparison of compounded semaglutide vs Wegovy including safety considerations, our dedicated guide covers the clinical and regulatory details patients need. You can also review common semaglutide side effects and how to manage them — the side effect profile is broadly similar regardless of whether the medication is compounded or brand-name.

Pros and Cons Summary

Final Verdict: Which Provider Wins in 2026?

For the majority of patients seeking affordable compounded GLP-1 therapy, Trimi is the clear financial winner. The math is straightforward: Trimi charges $99 per month total for compounded semaglutide and $125 per month total for compounded tirzepatide — with no membership fee, no platform surcharge, and no hidden costs. Mochi Health's equivalent all-in costs are $79 to $153 per month higher, driven entirely by the mandatory membership fee.

Mochi Health wins in specific categories: medication format variety (with its sublingual option), community scale (140K+ patient group), and review volume (14K+ Trustpilot reviews). For patients who need needle-free options or derive significant value from peer community, Mochi's higher price may be justified.

For everyone else — the majority of patients who are comfortable with weekly injections and primarily need high-quality, affordable GLP-1 therapy with competent clinical oversight — Trimi delivers the same class of compounded medication at dramatically lower cost. Over 12 months, Trimi patients on semaglutide save nearly $950. Tirzepatide patients save over $1,800. Those savings are real money that can fund other aspects of a healthy lifestyle.

If you are currently on Mochi Health and happy with your clinical results but looking to reduce your monthly spend, switching to Trimi is straightforward — your medication type, dosing schedule, and clinical oversight all continue uninterrupted. The only thing that changes is your bill. For more context on the full landscape of GLP-1 options, see our comprehensive GLP-1 provider ranking and our guide to managing common semaglutide side effects.